Monday, 24 March 2014 - 12:41
Bangladesh pushes biosimilar pharma JVs with Lanka.
For the first time, a government to government level cooperation effort is emerging to strengthen the supply of a crucial class of medicines in the 450 million dollars Lankan pharmaceutical market.
Bangladeshi pharmaceutical sector, which manufactures no less than 450 generic drugs for 5,300 registered brands, is now ready to partner with Sri Lanka to produce vital medicines used by seriously ill patients.
Bio-similar pharmaceutical products such as insulin, growth hormones, and hepatitis B vaccines, are used by critically ill patients.